09:01 AM EDT, 09/19/2025 (MT Newswires) -- Skye Bioscience ( SKYE ) said Friday that results from the phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease, or MASLD, demonstrated that the drug candidate was safe and well-tolerated.

Results also indicated that nimacimab has "predictable pharmacokinetics and low immunogenicity," according to the company. The company also said that the results showed no serious adverse events, and no evidence of neuropsychiatric safety signals.